Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 4/20 | 0.36 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.34 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13354410 | 0.78 | HPGDS (0.42) | HPGDSCYP2A6LTA4HBACE1CCNC | |
| Hydrochloric Acid SCHEMBL30555492 | 0.76 | HPGDS (0.41) | HPGDSLTA4HBACE1CCNCCDK8 | |
| SCHEMBL15883428 | 0.74 | NPC1 (0.51) | HPGDSLTA4HPOLB | |
| SCHEMBL31277144 | 0.74 | NPC1 (0.51) | HPGDSLTA4HPOLB | |
| SCHEMBL13737200 | 0.74 | HPGDS (0.53) | HPGDSCYP2A6LTA4HBACE1CCNC | |
| SCHEMBL19949791 | 0.74 | HPGDS (0.39) | HPGDSLTA4HBACE1CCNCCDK8 | |
| SCHEMBL14752258 | 0.74 | HPGDS (0.39) | HPGDSLTA4HBACE1CCNCCDK8 | |
| SCHEMBL14754891 | 0.74 | HPGDS (0.39) | HPGDSLTA4HBACE1CCNCCDK8 | |
| SCHEMBL14395774 | 0.74 | HPGDS (0.39) | HPGDSLTA4HBACE1CCNCCDK8 | |
| SCHEMBL16159872 | 0.74 | LTA4H (0.45) | HPGDSLTA4HBACE1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| EP-2908824-B1 | TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| EP-2747769-B1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2697210-B1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9499502-B2 | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499502-B2 | 5-substituted iminothiazines and their mono- and dioxides as BACE inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9416129-B2 | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416129-B2 | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9181236-B2 | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150284379-A1 | TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284379-A1 | TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20140200213-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200213-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140128382-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME LLC | 2014-05-08 | — | — | US | disclosed |
| US-20140128382-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME LLC | 2014-05-08 | — | — | US | disclosed |
| WO-2013028670-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012139425-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS,COMPOSITIONS,AND THEIR USE | SCHERING CORPORATION (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-1242426-B1 | GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | HPGDS 732/4885CYP2A6 3919/4885PTK2 4665/4885 |
| US-20140200213-A1 | 2-SPIRO-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO-AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE2, BACE1, APP | HPGDS 2196/4885CYP2A6 331/4885PTK2 1400/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | HPGDS 732/4885CYP2A6 3919/4885PTK2 4665/4885 |
| US-20140128382-A1 | 5-SUBSTITUTED IMINOTHIAZINES AND THEIR MONO- AND DIOXIDES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, PSEN1 | HPGDS 2648/4885CYP2A6 811/4885PTK2 2173/4885 |
| US-20150284379-A1 | TRICYCLIC SUBSTITUTED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE | BACE1, BACE2, APP | HPGDS 2767/4885CYP2A6 395/4885PTK2 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.